Camber Pharmaceuticals is pleased to announce that it has launched Esomeprazole Magnesium Delayed-Release Capsules, 20 mg and 40 mg, which is the generic version of Nexium(R) (Esomeprazole) capsules from AstraZeneca Pharmaceuticals. The product is indicated for the treatment of heartburn, gastroesophageal reflux disease (GERD), stomach ulcers, and for a damaged esophagus. Esomeprazole is available from Camber in 30, 90 and 1000 count bottles for both strengths.
"Esomeprazole represents as a significant product in the growth of our organization," said, Kon Ostaficiuk, President of Camber. "Our parent company, Hetero Labs Limited, has received the final approval for Esomeprazole ANDA from USFDA. Hetero Labs Limited has invested in the technology used to manufacture this challenging product and the results are reflected in the scale of our capacities. We are very happy to extend one more affordable treatment option to the patients in US."
Ostaficiuk added, "Our product pipeline continues to be impressive and it shows Camber's commitment to provide affordable medications in a wide variety of formulations and therapies in US."
Global leaders gather at the NFCR Summit to drive breakthroughs in cancer care